Got Patients With Refractory axSpA or PsA? Consider This Option

By News Health
19 hours Ago

(MedPage Today) — Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn’t respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should still be considered in such…

Source link : https://www.medpagetoday.com/rheumatology/arthritis/116666

Author :

Publish date : 2025-07-25 12:48:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

'My dad started spying on my mum' - the drugs causing sexual urges

10,000 steps myth - should you be a stickler for recommended daily doses?

Why we need to talk about periods, breasts and injuries

Solar drone with wingspan wider than jumbo jet could fly for months

Study Touts Benefit of Mini Nonhormonal IUD -- But It's Not Sold in the U.S.

Negative social ties, like frenemies, could be ageing you